Meihai Third Affiliated Hospital of Sun Yat-sen University Deng

Dr. Meihai Third Affiliated Hospital of Sun Yat-sen University Deng


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in International Journal of Biological Sciences
Verified
Journal Article
Open access
YTYongchang Tang
Yongchang Tang
LXLei Xu
Lei Xu
YRYupeng Ren
Yupeng Ren
YLYuxuan Li
Yuxuan Li
FYFeng Yuan
Feng Yuan
ZYZhicheng Yao
Zhicheng Yao
MVI has significant clinical value for treatment selection and prognosis evaluation in hepatocellular carcinoma (HCC). We aimed to construct a model based on MVI-Related Genes (MVIRGs) for risk assessment and prognosis prediction in patients with HCC. This study utilized various statistical analysis methods for prognostic model construction and validation in the Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) cohorts, respectively. In addition, immunohistochemistry and qRT-PCR were used to analyze and identify the value of the model in our cohort. After the analyses, 153 differentially expressed MVIRGs were identified, and three key genes were selected to construct a prognostic model. The high-risk group showed significantly lower overall survival (OS), and this trend was observed in all subgroups: different age groups, genders, stages, and grades. Risk score was a risk factor independent of age, gender, stage, and grade. Moreover, the ICGC cohort validated the prognostic value of the model corresponding to the TCGA. In our cohort, qRT-PCR and immunohistochemistry showed that all three genes had higher expression levels in HCC samples than in normal controls. High expression levels of genes and high-risk scores showed significantly lower recurrence-free survival (RFS) and OS, especially in MVI-positive HCC samples. Therefore, the prognostic model constructed by three MVIRGs can reliably predict the RFS and OS of patients with HCC and is valuable for guiding clinical treatment selection and prognostic assessment of HCC.

6 February 2021 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
JYJiarui Yang
Jiarui Yang
HLHao Liang
Hao Liang
KHKunpeng Hu
Kunpeng Hu
ZXZhiyong Xiong
Zhiyong Xiong
MCMingbo Cao
Mingbo Cao
MDMeihai Third Affiliated Hospital of Sun Yat-sen University Deng
Meihai Third Affiliated Hospital of Sun Yat-sen University Deng
Background: For patients with hepatocellular carcinoma (HCC) with microvascular invasion (MVI) after curative resection, the effects of various postoperative adjuvant therapies are not summarized in detail, and the comparison between the effects of various adjuvant therapies is still unclear. Thus, we collected existing studies on postoperative adjuvant therapies for patients with HCC with MVI after curative resection and analyzed the effects of various adjuvant therapies.Method: We collected all studies on postoperative adjuvant therapy for patients with HCC with MVI after curative resection from PubMed, EMBASE, Cochrane Library and SinoMed ending on May 1, 2019. Overall survival (OS) and disease-free/recurrence-free survival (RFS) between each group were compared in these studies by calculating the pooled hazard ratio (HR) and 95% confidence interval (CI). All statistical analyses were assessed by two authors independently.Result: A total of 13 studies were included in this study, including 824 postoperative adjuvant transarterial chemoembolization (pa-TACE) patients, 90 postoperative radiotherapy patients, 57 radiofrequency ablation (RFA)/re-resection patients, 16 sorafenib patients and 886 postoperative conservative treatment patients. The results showed that pa-TACE significantly improved OS and RFS compared with postoperative conservative treatment in patients with HCC with MVI after curative resection (HR: 0.64, 95% CI: 0.55–0.74, p < 0.001; HR: 0.70, 95% CI: 0.62–0.78, p < 0.001, respectively). There was no significant difference in OS between pa-TACE and radiotherapy in patients with HCC with MVI (HR: 1.75, 95% CI: 0.92–3.32, p = 0.087). RFS in patients with HCC with MVI after pa-TACE was worse than that after postoperative adjuvant radiotherapy (HR: 2.29, 95% CI: 1.43–3.65, p < 0.001). The prognosis of pa-TACE and RFA/re-resection in patients with MVI with recurrent HCC had no significant differences (HR: 0.65, 95% CI: 0.09–4.89, p = 0.671). Adjuvant treatments significantly improved the OS and RFS of patients compared with the postoperative conservative group (HR: 0.580, 95% CI: 0.480–0.710, p < 0.001; HR: 0.630, 95% CI: 0.540–0.740, p < 0.001, respectively).Conclusion: Compared with postoperative conservative treatment, pa-TACE, postoperative radiotherapy and sorafenib can improve the prognosis of patients with hepatocellular carcinoma with microvascular invasion after curative resection. Postoperative radiotherapy can reduce the recurrence of patients with HCC with MVI after curative resection compared with pa-TACE.

15 April 2025 in Advanced Science
Verified
Journal Article
Open access
YTYongchang Tang
Yongchang Tang
FYFeng Yuan
Feng Yuan
MCMingbo Cao
Mingbo Cao
YRYupeng Ren
Yupeng Ren
YLYuxuan Li
Yuxuan Li
ZYZhicheng Yao
Zhicheng Yao
Circular RNAs (circRNAs) are crucial regulators of targeted drug resistance in hepatocellular carcinoma (HCC). However, the specific mechanisms underlying resistance that significantly hampers the effectiveness of HCC treatments remain unclear. Here, it is found that circRNA‐mTOR is highly expressed in HCC and strongly correlated with patient prognosis. Furthermore, circRNA‐mTOR enhances the stemness of HCC cells, thereby promoting the progression of HCC and contributing to lenvatinib resistance. Mechanistically, circRNA‐mTOR promotes the nuclear translocation of the RNA‐binding protein (RBP) PC4 and SRSF1 interacting protein 1 (PSIP1) through specific binding. The enhancement of HCC cell stemness by circRNA‐mTOR occurs via the PSIP1/c‐Myc signaling pathway, ultimately driving HCC progression and lenvatinib resistance. This study highlights the important role of circRNA‐mTOR in HCC progression and the maintenance of lenvatinib resistance and underscores its potential as a biomarker for the diagnosis and prognosis of HCC. In conclusion, this study provides an experimental foundation for targeted drug therapy in HCC and offers novel insights, perspectives, and methodologies for understanding the development and occurrence of this disease. These findings are significant for the development of new diagnostic and therapeutic markers for HCC, with the ultimate goal of reducing drug resistance.

1 August 2018 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Closed access
ZYZhicheng Yao
Zhicheng Yao
ZXZhiyong Xiong
Zhiyong Xiong
RLRuixi Li
Ruixi Li
HLHao Liang
Hao Liang
CJChangchang Jia
Changchang Jia
MDMeihai Third Affiliated Hospital of Sun Yat-sen University Deng
Meihai Third Affiliated Hospital of Sun Yat-sen University Deng

15 July 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
CJChangchang Jia
Changchang Jia
ZYZhicheng Yao
Zhicheng Yao
ZLZexiao Lin
Zexiao Lin
LZLiyun Zhao
Liyun Zhao
XCXiurong Cai
Xiurong Cai
QZQi Zhang
Qi Zhang

1 January 2023 in Chinese Journal of Cancer Research
Verified
Journal Article
Closed access
GYGaoyuan Yang
Gaoyuan Yang
HYHuamei Yan
Huamei Yan
YTYongchang Tang
Yongchang Tang
FYFeng Yuan
Feng Yuan
MCMingbo Cao
Mingbo Cao
MDMeihai Third Affiliated Hospital of Sun Yat-sen University Deng
Meihai Third Affiliated Hospital of Sun Yat-sen University Deng
Primary liver cancer is a significant health problem worldwide. Hepatocellular carcinoma (HCC) is the main pathological type of primary liver cancer, accounting for 75%−85% of cases. In recent years, radiotherapy has become an emerging treatment for HCC and is effective for various stages of HCC. However, radiosensitivity of liver cancer cells has a significant effect on the efficacy of radiotherapy and is regulated by various factors. How to increase radiosensitivity and improve the therapeutic effects of radiotherapy require further exploration. This review summarizes the recent research progress on the mechanisms affecting sensitivity to radiotherapy, including epigenetics, transportation and metabolism, regulated cell death pathways, the microenvironment, and redox status, as well as the effect of nanoparticles on the radiosensitivity of liver cancer. It is expected to provide more effective strategies and methods for clinical treatment of liver cancer by radiotherapy.